NFKB2 Antikörper (N-Term)

Produktnummer ABIN116523

Produktdetails anti-NFKB2 Antikörper

Target: NFKB2 (Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells 2 (NFKB2))

Bindungsspezifität: N-Term

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser NFKB2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunoprecipitation (IP), Enzyme Immunoassay (EIA)

Spezifität: Anti-Human NFKB2 p52 may react non-specifically with other proteins. Control peptide (R1011CP) will compete only with the specific reaction of antiserum with Human NFKB2 p52.

Aufreinigung: Prepared from monospecific antiserum by delipidation and defibrination.

Immunogen: Human NFkB p52/p100 peptide corresponding to a region near the N-terminus of the human protein conjugated to Keyhole Limpet Hemocyanin (KLH).

Anwendungsinformationen

Applikationshinweise: Suitable for Western blotting (1/1000), Immunoprecipitation and ELISA. Use control peptide at 1 l per l of antiserum. Recommended Dilutions: This product was assayed by immunoblot and found to bereactive against Human NFKB2 p52 at a dilution of 1: 1000 followed by reaction withPeroxidase conjugated Affinity Purified anti-Rabbit IgG [H&L] (Goat). Anti-Human NFKB2p52 is suitable for the detection by immunoblot of Human NFKB2 p52 and its precursorprotein p100. Cross reactivity with p52 from other species may occur but has not beenspecifically determined. Reactivity in supershift assays has not been determined.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 90.0 mg/mL (by Refractometry)

Handhabung: Avoid repeated freezing and thawing.

Lagerung: -20 °C

Details zu NFKB2

Target: NFKB2 (Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells 2 (NFKB2))

Andere Bezeichnung: NFKB2 / NF-kappa-B p100/p52 (NFKB2 Produkte)

Synonyme: NF-kappaB2 antikoerper, lyt antikoerper, p49 antikoerper, p49/p100 antikoerper, p50B antikoerper, p52 antikoerper, nuclear factor of kappa light polypeptide gene enhancer in B cells 2, p49/p100 antikoerper, Nfkb2 antikoerper

Hintergrund: NFκB was originally identified as a factor that binds to the immunoglobulin kappa light chain enhancer in B cells. It was subsequently found in non-B cells in an inactive cytoplasmic form consisting of NFκB bound to IκB. NFκB was originally identified as a heterodimeric DNA binding protein complex consisting of p65 (RelA) and p50 (NFKB1) subunits. Other identified subunits include p52 (NFKB2), c-Rel, and RelB. The p65, cRel, and RelB subunits are responsible for transactivation. The p50 and p52 subunits possess DNA binding activity but limited ability to transactivate. p52 has been reported to form transcriptionally active heterodimers with the NFκB subunit p65, similar to p50/p65 heterodimers. The heterodimers of p52/p65 and p50/p65 are regulated by physical inactivation in the cytoplasm by an inhibitor called IκB-α. IκB-α binds to the p65 subunit, preventing nuclear localization and DNA binding. Low levels of p52 and p50 homodimers can also exist in cells.Synonyms: DNA-binding factor KBF2, H2TF1, KBF2, LYT10, Lymphocyte translocation chromosome 10, NF kappa B, NF-kB p100, NF-kB p52, Nuclear factor NF-kappa-B p100 subunit, Oncogene Lyt-10

Gen-ID: 4791

NCBI Accession: NP_001070961

UniProt: Q00653

Pathways: Toll-Like Receptors Cascades